Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of biomarker in predicting sensitivity of rectal cancer to preoperative chemoradiotherapy and surgical mesorectal resection

A biomarker, rectal cancer technology, applied in biochemical equipment and methods, microbial determination/inspection, drug combination, etc., can solve problems such as difficult to predict and sensitive

Inactive Publication Date: 2021-12-24
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although preoperative chemoradiotherapy combined with total mesorectal resection is the standard method for the treatment of patients with locally advanced rectal cancer, it is still difficult to predict which rectal cancer patients will be sensitive to the above combined therapy and predict the sensitivity of rectal cancer patients to treatment. Responsiveness or responsiveness remains a great challenge, therefore, the discovery of biomarkers that can be used to accurately predict the sensitivity of rectal cancer to preoperative chemoradiotherapy combined with total mesorectal resection, and its application to preoperative treatment-sensitive It is of great importance to the field in the screening of rectal cancer patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biomarker in predicting sensitivity of rectal cancer to preoperative chemoradiotherapy and surgical mesorectal resection
  • Application of biomarker in predicting sensitivity of rectal cancer to preoperative chemoradiotherapy and surgical mesorectal resection
  • Application of biomarker in predicting sensitivity of rectal cancer to preoperative chemoradiotherapy and surgical mesorectal resection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0097] Example 2 Verification of the diagnostic efficacy of genes S100P, SIGLEC5, and SEMA4B in predicting the sensitivity of rectal cancer patients to preoperative chemoradiotherapy combined with total mesorectal resection

[0098] 1. Experimental method

[0099] For the genes S100P, SIGLEC5, and SEMA4B that were differentially expressed between responders and non-responders screened in Example 1, the receiver operating characteristic (ROC) analysis was performed using the R package "pROC" (version 1.15.0), and the calculation The area under the receiver operating characteristic curve (AUC) was used to evaluate the effect of genes S100P, SIGLEC5, SEMA4B, S100P+SIGLEC5, S100P+SEMA4B, SIGLEC5+SEMA4B, S100P+SIGLEC5+SEMA4B on the prediction of colorectal cancer patients in the training set and validation set, respectively. Accuracy of preoperative chemoradiotherapy combined with total mesorectal resection for treatment sensitivity, wherein the AUC value ranges from 0 to 1;

[01...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a biomarker in predicting sensitivity of rectal cancer to preoperative chemoradiotherapy and surgical mesorectal resection. The biomarker is S100P, SIGLEC5 and / or SEMA4B, and verification shows that the biomarker has relatively good diagnostic efficiency in predicting sensitivity or reactivity of rectal cancer patients to operative treatment, and is relatively high in AUC value; and the application provides a new strategy and thought for clinically treating the rectal cancer, and also provides a candidate target for developing medicines for improving the treatment sensitivity of the rectal cancer patients to the preoperative chemoradiotherapy and surgical mesorectal resection.

Description

technical field [0001] The present invention belongs to the technical field of biomedicine. Specifically, the present invention relates to the application of biomarkers in predicting the sensitivity of rectal cancer to preoperative radiotherapy and chemotherapy combined with total mesorectal resection. More specifically, the present invention relates to the biomarker S100P , SIGLEC5, and / or SEMA4B in predicting the sensitivity of rectal cancer to preoperative chemoradiotherapy combined with total mesorectal resection. Background technique [0002] Rectal cancer is one of the most common malignant tumors of the digestive tract, which refers to the cancer between the dentate line and the rectosigmoid junction. Its incidence rate ranks third among malignant tumors in my country, and its mortality rate ranks fifth among malignant tumors in my country. It has the epidemiological characteristics of younger age of onset and higher incidence. According to data, middle and low recta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574A61K45/00A61P35/00G16H20/40G16B50/00
CPCC12Q1/6886G01N33/57446G01N33/57484A61K45/00A61P35/00G16H20/40G16B50/00C12Q2600/106C12Q2600/158
Inventor 杨承刚王丹
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products